When is Norvasc's Patent Expected to Expire?
Norvasc (amlodipine besylate), originally developed by Pfizer, has long passed its primary patent protection. While specific patent expiration dates can be complex due to various exclusivities and subsequent patents, the foundational patents for Norvasc have expired, allowing for generic versions to be available [1].
What is Viatris's Role with Norvasc Generics?
Viatris, a pharmaceutical company formed by the merger of Pfizer's Upjohn division and Mylan, is involved in the production and distribution of generic medications, including amlodipine besylate, the active ingredient in Norvasc [2]. This means Viatris is a supplier of generic Norvasc.
How Does Generic Amlodipine Compare to Brand-Name Norvasc?
Generic amlodipine besylate is bioequivalent to brand-name Norvasc. Regulatory bodies like the U.S. Food and Drug Administration (FDA) require generic drugs to demonstrate they have the same active ingredient, dosage form, strength, route of administration, quality, performance characteristics, and intended use as the brand-name product [3]. Therefore, generic amlodipine is expected to work in the same way as Norvasc.
What are the Benefits of Generic Medications like Amlodipine?
The availability of generic medications, such as amlodipine besylate, significantly reduces healthcare costs by offering a more affordable alternative to brand-name drugs [3]. This can improve patient access to essential treatments for conditions like hypertension.
Where Can I Find Information on Drug Patents?
Resources like DrugPatentWatch.com provide databases and insights into drug patent status, expiration dates, and exclusivities for a wide range of pharmaceuticals, including medications like Norvasc [1].
*
**Sources:
1. DrugPatentWatch.com
2. Viatris Company Information
3. U.S. Food and Drug Administration (FDA) - Generics